Skip to main content

Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2025.

via HealthDay

WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than placebo, according to a study published online April 23 in the New England Journal of Medicine.

Luke J. Laffin, M.D., from the Cleveland Clinic Foundation, and colleagues conducted a double-blind, randomized trial involving patients who were receiving two to five antihypertensive medications and had a blood pressure measurement of 140/90 mm Hg or higher obtained during an office visit. Participants underwent a standardized antihypertensive regimen for three weeks; those with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were randomly assigned to receive placebo, lorundrostat (50 mg daily; stable-dose group), or lorundrostat starting at 50 mg daily and increasing to 100 mg daily if systolic blood pressure was ≥130 mm Hg after four weeks (dose-adjustment group).

Two hundred eighty-five patients were randomly assigned: 94, 96, and 95 to the stable-dose group, dose-adjustment group, and placebo group, respectively. The researchers found that after 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was –15.4, –13.9, and –7.4 mm Hg in the stable-dose, dose-adjustment, and placebo groups, respectively. The placebo-adjusted change in blood pressure was –7.9 and –6.5 mm Hg in the stable-dose and dose-adjustment groups, respectively. In the combined lorundrostat groups, the placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 was –5.3 mm Hg.

"Aldosterone synthase inhibition with lorundrostat effectively lowered blood pressure in patients with uncontrolled and treatment-resistant hypertension," the authors write.

Several authors disclosed ties to biopharmaceutical, medical device, and medical technology companies, including Mineralys Therapeutics, which is developing lorundrostat and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Only 36.4 Percent of U.S. Adults Had No CVD Risk Factors in Recent Years

WEDNESDAY, Sept. 24, 2025 -- During August 2021 to August 2023, only 36.4 percent of U.S. adults had no cardiovascular disease (CVD) risk factors, according to a September data...

Three Cardiometabolic Risk Factors ID'd as Having the Highest Risk for Mortality in MASLD

TUESDAY, Sept. 23, 2025 -- For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the cardiometabolic risk factors (CMRFs) of high blood pressure...

Methotrexate Cuts Systolic BP in Rheumatoid Arthritis

MONDAY, Sept. 15, 2025 -- For patients with rheumatoid arthritis (RA), methotrexate significantly reduces systolic blood pressure (SBP), according to a study published online July...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.